InspireMD Inc NSPR

NAS: NSPR | ISIN: US45779A8466 2/06/2023

1,778 USD (-3,88%)

(-3,88%) 2/06/2023

Toon enkel gratis nieuws

9 maart 2021 · InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results · Persbericht

2 maart 2021 · InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update · Persbericht

24 februari 2021 · InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States · Persbericht

9 februari 2021 · InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States · Persbericht

8 februari 2021 · InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option · Persbericht

4 februari 2021 · InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering · Persbericht

3 februari 2021 · InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China · Persbericht

26 januari 2021 · InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe